News coverage about Pacific Biosciences (NASDAQ:PACB) has been trending positive this week, Accern reports. Accern identifies positive and negative news coverage by reviewing more than 20 million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Pacific Biosciences earned a coverage optimism score of 0.38 on Accern’s scale. Accern also assigned news coverage about the biotechnology company an impact score of 47.3004934548277 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the near term.
These are some of the news stories that may have effected Accern’s rankings:
- Pacific Biosciences (PACB) Upgraded to “Sell” by BidaskClub (americanbankingnews.com)
- Genome Sequencing Roundup (seekingalpha.com)
- Technical Review of Pacific Biosciences of California, Inc. (NASDAQ:PACB) (oracleexaminer.com)
- Notable Traders Recap: Huntington Bancshares Incorporated, (NASDAQ: HBAN), Pacific Biosciences of California, Inc … (globalexportlines.com)
- Attention Seeking Stock – Pacific Biosciences of California, (NASDAQ: PACB) (stocksnewstimes.com)
Shares of NASDAQ:PACB traded up $0.10 during midday trading on Thursday, hitting $2.42. The company had a trading volume of 748,399 shares, compared to its average volume of 1,133,929. Pacific Biosciences has a twelve month low of $2.02 and a twelve month high of $5.70. The company has a debt-to-equity ratio of 0.16, a quick ratio of 2.74 and a current ratio of 3.55. The stock has a market cap of $292.75, a PE ratio of -2.78 and a beta of 1.61.
A number of equities analysts have commented on PACB shares. BidaskClub cut Pacific Biosciences from a “sell” rating to a “strong sell” rating in a report on Saturday, January 13th. Zacks Investment Research cut Pacific Biosciences from a “hold” rating to a “sell” rating in a report on Tuesday, January 9th. Three research analysts have rated the stock with a sell rating, two have assigned a hold rating and one has assigned a buy rating to the company. The company presently has an average rating of “Hold” and an average price target of $6.27.
Pacific Biosciences Company Profile
Pacific Biosciences of California, Inc designs, develops, and manufactures sequencing systems to resolve genetically complex problems. The company's single molecule real-time (SMRT) sequencing technology enables single molecule real-time detection of biological processes. It offers PacBio RS II and Sequel Systems that conducts, monitors, and analyzes single molecule biochemical reactions in real time.
Receive News & Ratings for Pacific Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pacific Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.